Clinical Trial Update: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on Avutometinib (VS-6766) and Defactinib in combination with gemcitabine and nab-paclitaxel for pancreatic cancer, sponsored by Verastem, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Avutometinib (VS-6766) (Avutometinib)
• Defactinib (defactinib)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Verastem, Inc. | Conditions: KRAS Activating Mutation, Metastatic Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING